Search results
View the latest Gossamer Bio Inc. (GOSS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
3 days ago · 0.59 USD. +1.90%. -4.82%. -35.34%. May. 07. Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024. CI. May. 06. Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications.
52 Week Low 0.45. 52 Week Low Date 10/24/23. Market Cap 132.134M. Shares Out 226.22M. 10 Day Average Volume 1.44M. Dividend -. Dividend Yield -. Beta 1.90. YTD % Change -35.99.
Dec 6, 2022 · Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). A mean difference in pulmonary ...
4 days ago · A. The latest price target for Gossamer Bio ( NASDAQ: GOSS) was reported by HC Wainwright & Co. on Monday, May 20, 2024. The analyst firm set a price target for 10.00 expecting GOSS to rise to ...
Gossamer Bio, Inc. (GOSS) NasdaqGS - NasdaqGS Real-time price. Currency in USD. As of 09:59AM EDT. Market open. Find the latest Gossamer Bio, Inc. (GOSS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Mar 5, 2024 · InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Gossamer Bio (NASDAQ: GOSS) just reported results for the fourth quarter of 2023. Gossamer Bio reported earnings per share of -21 cents.
